Milestone Pharmaceuticals Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
MIST$0.66-10.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Loss
Condensed Consolidated Statements of Loss** (Unaudited)**
(in thousands of US dollars, except share and per share data)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · · | |||||||
| · · Three months ended March 31, · | |||||||
| · · 2026 · · 2025 · | |||||||
| | | | | | | | |
| Revenues | | | | | | | |
| Product revenue, net | | $238 | | $— | | ||
| License and other revenue | | | — | | | — | |
| Total revenues | | | 238 | | | — | |
| | | | | | | | |
| Operating Expenses | | | | | | | |
| Cost of product sales | | | 14 | | | — | |
| Research and development, net of tax credits | | | 3,251 | | 4,978 | | |
| General and administrative | | | 4,824 | | 5,167 | | |
| Commercial | | | 15,812 | | 10,378 | | |
| Total operating expenses | | | 23,901 | | | 20,523 | |
| | | | | | | | |
| Loss from operations | | | (23,663) | | (20,523) | | |
| | | | | | | | |
| Interest income | | | 1,732 | | 697 | | |
| Interest expense | | | (4,135) | | | (935) | |
| | | | | | | | |
| Net loss and comprehensive loss | | $(26,066) | $(20,761) | | |||
| | | | | | | | |
| Weighted average number of shares and pre-funded warrants outstanding, basic and diluted | | | 130,286,033 | | | 66,285,406 | |
| | | | | | | | |
| Net loss per share, basic and diluted | | $(0.20) | $(0.31) | | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.